Biotech’s Big Gamble Fails: Insights and Implicationsby Lilu Anderson 18.06.2024Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
7 Breakthrough Biotech Stocks to Boost Your Portfolio in 2023by Lilu Anderson 18.06.2024"Discover 7 breakthrough biotech stocks poised to boost your portfolio in a sector projected to reach $521.6B by 2033. Learn ...
Aerovate Therapeutics Stock Downgraded After Trial Setbackby Mark Eisenberg 17.06.2024Aerovate Therapeutics stock downgraded by BTIG after AV-101 trial setback; mixed analyst views and future pivotal readouts crucial for investors.
Roche’s Hemlibra Battles Fierce Competition Amid Rating Holdby Mark Eisenberg 17.06.2024Roche's Hemlibra braces for fierce competition from Novo Nordisk's mim8, as analysts give mixed ratings and forecasts on Roche's strategic ...
Crypto Deposits to Chinese Drug Producers Double in 2024by John Darbie 16.06.2024Bitcoin dominates with 60% of crypto transaction volume. TRON and Ethereum follow. 70% of drug precursor sales linked to 11 ...
Avidity Biosciences CFO Sells $3.7M in Stock Amid Positive Newsby Terry Bingman 15.06.2024Avidity Biosciences sees share ownership shift as MacLean reduces holding under Rule 10b5-1 Plan; positive sector developments bolster outlook.
Avidity Biosciences Director Sells $3.8M in Stockby Mark Eisenberg 15.06.2024Arthur A. Levin sells 40K Avidity shares; BofA ups target to $45 as FDA advances myotonic dystrophy treatment. AI-assisted article ...
Tempus AI Raises $410M in IPO, Sees Revenue Surgeby Mark Eisenberg 15.06.2024Tempus AI sold 11M shares at $37 each, launched in 2015, focuses on medical testing, with revenue growth from $320.7M ...
Novo Nordisk CEO to Testify on High Prices of Ozempic, Wegovyby Mark Eisenberg 15.06.2024Senate subpoenas Novo's Langa over drug pricing; Jorgensen to testify in September as Novo blames U.S. health system for high ...
Altimmune’s Promising GLP-1 Drug: Worth the Investment?by Mark Eisenberg 25.04.2024Altimmune's stock has seen a strong increase in value, surpassing Eli Lilly and Novo Nordisk. However, there are risks involved.